Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.67 |
| ▸ | FLT3 | P36888 | 3/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | FLT1 | P17948 | 2/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | FLT4 | P35916 | 2/20 | 0.64 |
| ▸ | JAK3 | P52333 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001299 | 1.00 | RET (0.70) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL6001458 | 0.83 | CCNE1 (0.74) | RETPDGFRBPDPK1JAK3MEN1 | |
| SCHEMBL6001461 | 0.83 | CCNE1 (0.74) | RETPDGFRBPDPK1JAK3MEN1 | |
| SCHEMBL19979 | 0.80 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL29394706 | 0.80 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL13081086 | 0.80 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL19978 | 0.80 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5478517 | 0.80 | PDPK1 (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5475962 | 0.80 | PDGFRB (0.81) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL31726696 | 0.80 | RET (0.76) | RETPDGFRBKDRFLT3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| EP-0769947-B1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 2001-05-02 | — | — | EP | claimed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | claimed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6846839-B1 | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis | SUGEN, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | SUGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | RET 85/4885PDGFRB 325/4885KDR 460/4885 |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | RET 4729/4885PDGFRB 2159/4885KDR 3586/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | RET 2946/4885PDGFRB 1819/4885KDR 3600/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | RET 2849/4885PDGFRB 2095/4885KDR 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.